Alpha-Lipoic Acid

An antioxidant with genuine evidence for diabetic neuropathy symptoms and modest insulin-sensitivity effects.

Overall grade: Grade B
Last revised: Jul 10, 2026; 2
graded outcomes: 0
references listed

Compare with another entry See it in the matrix →

A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.

3 at grade B — 3 graded rows

What is known

Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.

Outcome	Grade	Effect size	Agreement
Diabetic neuropathy symptomsIncluding IV data	Evidence grade B	Moderate	mixed
Insulin sensitivity / glucoseModest	Evidence grade B	Small	mixed

Diabetic neuropathy symptomsEvidence grade B
Including IV data
Moderatemixed
Insulin sensitivity / glucoseEvidence grade B
Modest
Smallmixed

Conditions

How the entry reads its effect on diagnosed conditions: the direction first, then the grade. Never a substitute for the person who treats you.

Diabetic neuropathy ImprovesEvidence grade BSymptom reliefGrade B

What is uncertain

Read off the same rows as above. Nothing here is added that the entry does not itself record.

Studies disagree: Diabetic neuropathy symptoms (mixed agreement); Insulin sensitivity / glucose (mixed agreement).
Caution with Metformin: Additive glucose lowering — watch for lows.
Caution with Berberine: Stacking glucose-lowering agents multiplies monitoring needs.
Watch with Berberine: Stacking glucose-lowering agents multiplies monitoring needs.

Interactions

Documented pairings with supplements and medicines. A medicine on this list is a conversation for whoever prescribes it.

MetforminCaution
Additive glucose lowering — watch for lows.
BerberineCaution
Stacking glucose-lowering agents multiplies monitoring needs.

The evidence in words

What it is

Alpha-lipoic acid is a mitochondrial antioxidant that is both fat- and water-soluble, studied mainly in diabetes.

How it works

It regenerates other antioxidants and improves insulin signaling and nerve microcirculation, the basis for its neuropathy use.

What the evidence shows

Reasonable evidence (including intravenous trials) supports symptom relief in diabetic peripheral neuropathy, and oral ALA modestly improves insulin sensitivity and fasting glucose. It stacks additively with glucose-lowering drugs, so monitoring matters.

How to use it

300–600 mg/day (R-ALA is the active isomer); take on an empty stomach for absorption.

Safety & interactions

Generally safe; can lower glucose (watch for lows with diabetes meds) and rarely triggers an insulin-autoimmune reaction. metformin — Additive glucose lowering — watch for lows. Berberine — Stacking glucose-lowering agents multiplies monitoring needs.

Bottom line

A legitimate option for diabetic neuropathy symptoms and mild glucose improvement. 300–600 mg/day; coordinate with any diabetes medication.

How it is used

As the entry records it, from the studies it summarises. Not a recommendation for you — doses that suit a trial population may not suit you.

Standard: 300–600 mg/day, empty stomach.

Entries that share this one's tags or conditions.

Alpha-Lipoic Acid for Diabetic neuropathyEvidence grade B — Symptom reliefEvidence grade B
Alpha-Lipoic Acid for Diabetic neuropathy symptomsEvidence grade B — Including IV dataEvidence grade B
Alpha-Lipoic Acid for Insulin sensitivity / glucoseEvidence grade B — ModestEvidence grade B
Alpha-Lipoic Acid: dosage and how to take it300–600 mg/day, empty stomach.Evidence grade B

Sources

This entry lists no references of its own.

Last revised Jul 10, 2026. A grade is this entry's reading of the evidence, not medical advice.